Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition

被引：101

作者：

Mahmud, A

Feely, J ^{[1
]}

机构：

[1] St James Hosp, Dept Pharmacol & Therapeut, Trin Ctr Hlth Sci, Dublin 8, Ireland

[2] St James Hosp, Hypertens Clin, Dublin 8, Ireland

来源：

AMERICAN JOURNAL OF HYPERTENSION | 2002年 / 15卷 / 04期

关键词：

arterial stiffness; hypertension; angiotensin II antagonist;

D O I：

10.1016/S0895-7061(01)02313-5

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

We measured the effects of angiotensin 11 blockade on arterial stiffness, augmentation index (AI%), pulse wave velocity (PWV), and blood pressure (BP) in 12 hypertensive patients (mean 49 +/- 11 years) in a 4-week, randomized, cross-over study comparing valsartan 160 mg/day with captopril 100 mg/day, with a 2-week washout period. Subsequently both therapies were combined. Reductions in PWV and AI% remained significant when corrected for BP. Combined therapy reduced PWV and AI% (P <.05) more than monotherapy, even when corrected for BP. The study shows that angiotensin receptor antagonists reduce arterial stiffness in hypertension comparable with and possibly additive to angiotensin converting enzyme inhibition. (C) 2002 American Journal of Hypertension, Ltd.

引用

收藏

页码：321 / 325

页数：5

相关论文

共 15 条

[1] In vivo angiotensin II receptor blockade and converting enzyme inhibition on canine aortic viscoelasticity [J].

Barra, JG ;

Levenson, J ;

Armentano, RL ;

Fischer, EIC ;

Pichel, RH ;

Simon, A .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1997, 272 (02) :H859-H868

[2]

CHEN CH, 1996, HYPERTENSION, V27, P175

[3] Blockade of the renin-angiotensin-aldosterone system with combination angiotensin receptor antagonist and ACE inhibitor therapy: Observations from Val-HeFT and CALM [J].

Chin, BSP ;

Lip, GYH .

JOURNAL OF HUMAN HYPERTENSION, 2001, 15 (02) :89-92

[4] Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension [J].

Ghiadoni, L ;

Virdis, A ;

Magagna, A ;

Taddei, S ;

Salvetti, A .

HYPERTENSION, 2000, 35 (01) :501-506

[5]

Guerin AP, 2001, CIRCULATION, V103, P987

[6] Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease - Role of superoxide dismutase [J].

Hornig, B ;

Landmesser, U ;

Kohler, C ;

Ahlersmann, D ;

Spiekermann, S ;

Christoph, A ;

Tatge, H ;

Drexler, H .

CIRCULATION, 2001, 103 (06) :799-805

[7] Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure [J].

Jorde, UP ;

Ennezat, PV ;

Lisker, J ;

Suryadevara, V ;

Infeld, J ;

Cukon, S ;

Hammer, A ;

Sonnenblick, EH ;

Le Jemtel, TH .

CIRCULATION, 2000, 101 (08) :844-846

[8] Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients [J].

Laurent, S ;

Boutouyrie, P ;

Asmar, R ;

Gautier, I ;

Laloux, B ;

Guize, L ;

Ducimetiere, P ;

Benetos, A .

HYPERTENSION, 2001, 37 (05) :1236-1241

[9]

LEVY PF, 1991, BIOPHARM-TECHNOL BUS, V4, P24

[10] Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition [J].

London, GM ;

Pannier, B ;

Vicaut, E ;

Guerin, AP ;

Marchais, SJ ;

Safar, ME ;

Cuche, JL .

JOURNAL OF HYPERTENSION, 1996, 14 (09) :1139-1146